AIDS-related Kaposi's sarcoma: Evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group staging system in the Haart era - The Italian Cooperative Group on AIDS and tumors and the Italian cohort of patients naïve from antiretrovirals

Journal of Clinical Oncology

Volumn 21, Issue 15, 2003, Pages 2876-2882

  Nasti, Guglielmo ^a   Talamini, Renato ^a   Antinori, Andrea ^a   Martellotta, Ferdinando ^a   Jacchetti, Gaia ^a   Chiodo, Francesco ^a   Ballardini, Giuseppe ^a   Stoppini, Laura ^a   Di Perri, Giovanni ^a   Mena, Maurizio ^a   Tavio, Marcello ^a   Vaccher, Emanuela ^a   Monforte, Antonella D'Arminio ^a   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE DISTRIBUTION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; VIREMIA; ADULT; AGED; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; ITALY; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SURVIVAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS; FEMALE; HIV-1; HUMANS; ITALY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SARCOMA, KAPOSI; SURVIVAL ANALYSIS;

EID: 0042386692     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.162     Document Type: Article

References (24)

1. Brodt HR, Kamps BS, Gute P: Changing incidence of AIDS-defining illness in the era of antiretroviral combination therapy. AIDS 11:1731-1738, 1997
2. Jacobson LP, Yamishita TE, Detels R, et al: Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. J Acquir Immune Defic Syndr 21:S34-S41, 1999
3. Jones JL, Hanson DL, Dworkin MS, et al: Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. J Acquir Immune Defic Syndr 21:S11-S17, 1999
4. Powderly WG, Landay A, Lederman MM: Recovery of the immune system with antiretroviral therapy. The end of opportunism? JAMA 280:72-77, 1998
5. Dupont C, Vasseur E, Beauchet A, et al: Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. AIDS 14:987-993, 2000
6. Vaccher E, di Gennaro G, Nasti G, et al: HAART is effective as anti-Kaposi's sarcoma therapy only after remission has been induced by chemotherapy. J Acquir Immune Defic Syndr 22:407-408, 1999
7. Cattelan AM, Calabro ML, Aversa SML, et al: Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: Biological correlates of clinical outcome. Eur J Cancer 35:1809-1815, 1999
8. Dezube BJ: New therapies of the treatment of AIDS-related Kaposi's sarcoma. Curr Opin Oncol 12:445-449, 2000
9. Tavio M, Nasti G, Spina M, et al: Highly active antiretroviral therapy in HIV-related Kaposi's sarcoma. Ann Oncol 9:923, 1998
10. Lebbé C, Blum L, Pellet C, et al: Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 12:F45-F49, 1998
11. Nasti G, Errante D, Santarossa S, et al: A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma. Drug Saf 20:403-425, 1999
12. Ensoli B, Stürzl M: Kaposi's sarcoma: A result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. Cytokine Growth Factor 9:63-83, 1998
13. Krown SE, Metroka C, Wernz JC: Kaposi's sarcoma in the acquired immune deficiency syndrome: A proposal for uniform evaluation, response and staging criteria. J Clin Oncol 7:1201-1207, 1989
14. Krown SE, Testa MA, Huang J: AIDS-related Kaposi's sarcoma: Prospective validation of the AIDS Clinical Trials Group Staging Classification. J Clin Oncol 15:3085-3092, 1997
15. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Cox DR: Regression model and life-tables. J R Stat Soc B34:178-220, 1972
17. Tam HK, Zhang ZF, Jacobson LP, et al: Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi's sarcoma or non-Hodgkin's lymphoma. Int J Cancer 98:916-922, 2002
18. Bower M, Fox P, Fife K, et al: Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 13:2105-2111, 1999
19. Sgadari C, Barillari G, Toschi E, et al: HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi's sarcoma. Nat Med 8:225-232, 2002
20. Pati S, Pelser CB, Dufraine J, et al: Antitumorigenic effects of HIV protease inhibitor ritonavir: Inhibition of Kaposi sarcoma. Blood 99:3771-3779, 2002
21. Quinlivan EB, Zhang C, Stewart PW, et al: Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's disease progression, but elevated levels of human immunodeficiency virus type 1 do not. J Infect Dis 185:1736-1744, 2002
22. Pellet C, Chevret S, Francès C, et al: Prognostic value of quantitative Kaposi sarcoma-associated herpesvirus load in posttransplatation Kaposi sarcoma. J Infect Dis 186:110-113, 2002
23. Pellet C, Chevret S, Blum L, et al: Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol 117:858-863, 2001
24. Holkova B, Takeshita K, Cheng DM, et al: Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol 19:3848-3851, 2001